logo

For the Inventor, By the Inventor

Marseille, France

Innate Pharma


USPTO Granted Patents = 68

% Expired Patents = 13.2



Trademarks = 1

Forward Citations = 240

Loading Chart...
Loading Chart...

68 inventors (with patents filed for the assignee):

goldMedal Laurent Gauthier (37 out of 42 patents)

silverMedal Carine Paturel (24 out of 25 patents)

bronzeMedal Benjamin Rossi (20 out of 20 patents)

4.  Mathieu Blery (12 out of 14 patents)

5.  Nadia Anceriz (10 out of 10 patents)

6.  Pascale Andre (10 out of 18 patents)

7.  Nicolai Wagtmann (9 out of 13 patents)

8.  Hélène Sicard (9 out of 9 patents)

9.  Ivan Perrot (8 out of 9 patents)

10.  Delphine Bregeon (8 out of 8 patents)

11.  Ariane Morel (7 out of 7 patents)

12.  Patrick Dennler (7 out of 7 patents)

13.  Eliane Fischer (7 out of 7 patents)

14.  Roger Schibli (6 out of 24 patents)

15.  Christian Belmant (6 out of 14 patents)


Core Competencies:
NK Cell Engagers
CD73 Blocking Antibodies
T Cell Lymphoma
Siglec Neutralizing Antibodies
KIR3DL2 Binding Agents
NKG2A Antibodies
Humanized Antibodies
Enzymatic Conjugation
Multispecific Proteins
TLR3 Binding Agents
Combination Therapy
Cancer Treatment

68 patents:

1. 12594343 - TREATMENT OF CANCER (2026-04-07),
2. 12528876 - CD73 BLOCKING ANTIBODIES (2026-01-20),
3. 12448442 - Treatment of T cell lymphoma (2025-10-21),
4. 12365731 - NKp46 binding agents (2025-07-22),
5. 12252543 - Multispecific NK engager protein (2025-03-18),
6. 12227569 - Humanized antibodies with increased stability (2025-02-18),
7. 12209126 - Treatment of cancer (2025-01-28),
8. 12202907 - Nucleic acids encoding and methods of producing proteins comprising antibody chains (2025-01-21),
9. 12084498 - Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma (2024-09-10),
10. 12037392 - Treatment regimens using anti-NKG2A antibodies (2024-07-16),
11. 11999784 - Treatment of peripheral T cell lymphoma (2024-06-04),
12. 11970535 - Treatment with anti-KIR3DL2 agents (2024-04-30),
13. 11958907 - CD73 blockade (2024-04-16),
14. 11891444 - Variable regions for NKp46 binding proteins (2024-02-06),
15. 11858990 - KIR3DL2 binding agents (2024-01-02),
Innate Pharma is a clinical-stage biotechnology company that specializes in developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases. Their innovative approach harnesses the innate immune system to fight diseases. With a diverse pipeline of drug candidates and partnerships with leading pharmaceutical companies, Innate Pharma aims to bring new treatment options to patients in need.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Innate Pharma
68 Patents

#1 in Marseille

#380 in France

#10,868 in the World

Marseille, FR
Marseille, France

Innate Pharma

Forward Citations = 240

68 inventors:

goldMedal Laurent Gauthier (37 out of 42 patents)

silverMedal Carine Paturel (24 out of 25 patents)

bronzeMedal Benjamin Rossi (20 out of 20 patents)

4.  Mathieu Blery (12 out of 14 patents)

5.  Nadia Anceriz (10 out of 10 patents)

Please report any incorrect information to [email protected]
Loading…